Vanda Pharmaceuticals Inc. (VNDA)

21.11
0.99 4.90
NASDAQ : Health Technology
Prev Close 20.12
Open 20.12
Day Low/High 19.70 / 21.14
52 Wk Low/High 13.88 / 33.44
Volume 1.58M
Avg Volume 802.00K
Exchange NASDAQ
Shares Outstanding 52.45M
Market Cap 966.13M
EPS -0.30
P/E Ratio 76.75
Div & Yield N.A. (N.A)
Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Vanda Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Vanda Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results

Vanda Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results

- Full year 2018 total revenues grew to $193.1 million, a 17% increase compared to 2017

VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

NEW YORK, Feb. 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vanda Pharmaceuticals Inc.

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Vanda Pharmaceuticals Inc.

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Vanda Pharmaceuticals Inc.

NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Vanda Pharmaceuticals Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Vanda Pharmaceuticals Inc.

The law firm of Kirby McInerney LLP is investigating potential claims against Vanda Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Vanda Pharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Vanda Pharmaceuticals Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Vanda Pharmaceuticals Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DHX, EWBC, KE, MSON, OMN, RDWR, RNR, SEE Downgrades: AR, FTAI, K, RYN, SNY, TWO, VNDA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vanda Pharmaceuticals Takes A Stand Against Unnecessary Animal Research

Vanda Pharmaceuticals Takes A Stand Against Unnecessary Animal Research

Company pursuing legal action against the FDA for requiring unnecessary studies that would result in the death of dozens of dogs without legal authority.

First Week Of February 15th Options Trading For Vanda Pharmaceuticals (VNDA)

First Week Of February 15th Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application For Review In The Treatment Of Jet Lag Disorder

FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application For Review In The Treatment Of Jet Lag Disorder

WASHINGTON, Dec. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Announces Positive Pivotal Study Results For HETLIOZ® (tasimelteon) In Patients With Smith-Magenis Syndrome

Vanda Announces Positive Pivotal Study Results For HETLIOZ® (tasimelteon) In Patients With Smith-Magenis Syndrome

WASHINGTON, Dec. 10, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reaches Analyst Target Price

Vanda Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Vanda Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $29.40, changing hands for $31.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Vanda Announces Positive Phase II Study Results For Tradipitant In Patients With Gastroparesis

Vanda Announces Positive Phase II Study Results For Tradipitant In Patients With Gastroparesis

Management to host conference call on Monday, December 3 at 8:30 AM ET

First Week Of January 2019 Options Trading For Vanda Pharmaceuticals (VNDA)

First Week Of January 2019 Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

Vanda Pharmaceuticals Announces Participation At November 2018 Investor Conferences

Vanda Pharmaceuticals Announces Participation At November 2018 Investor Conferences

WASHINGTON, Nov. 8, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results

Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results

-- Hetlioz® net product sales grew to $29.9 million in the third quarter of 2018, a 34% increase compared to the third quarter of 2017

Vanda Receives FDA Letter Regarding Corporate Webpage

Vanda Receives FDA Letter Regarding Corporate Webpage

WASHINGTON, Nov. 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AZPN, COG, FBP, GCAP, SPSC, TWTR, USAK, VNDA Downgrades: ALK, CCK, CRM, EIGI, FBHS, GWRE, HOFT, HOPE, LAWS, LEG, MAS, MRVL, VREX, VTR, WRK Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vanda Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 7, 2018

Vanda Pharmaceuticals To Announce Third Quarter 2018 Financial Results On November 7, 2018

Conference Call and Webcast to Follow

Vanda Pharmaceuticals Announces Participation At Oppenheimer And Cantor Fitzgerald Fall 2018 Investor Conferences

Vanda Pharmaceuticals Announces Participation At Oppenheimer And Cantor Fitzgerald Fall 2018 Investor Conferences

WASHINGTON, Sept. 26, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Rollins Set To Join S&P 500; Inogen To Join S&P MidCap 400; Vanda Pharmaceuticals And Garrett Motion To Join S&P SmallCap 600

Rollins Set To Join S&P 500; Inogen To Join S&P MidCap 400; Vanda Pharmaceuticals And Garrett Motion To Join S&P SmallCap 600

NEW YORK, Sept. 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Rollins Inc.

Vanda Announces Listing Of A New HETLIOZ® Patent In The FDA Orange Book

Vanda Announces Listing Of A New HETLIOZ® Patent In The FDA Orange Book

WASHINGTON, Sept. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment In Next Morning Performance

HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment In Next Morning Performance

WASHINGTON, Sept. 12, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation At September 2018 Investor Conferences

Vanda Pharmaceuticals Announces Participation At September 2018 Investor Conferences

WASHINGTON, Sept. 4, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Interesting VNDA Put And Call Options For August 17th

Interesting VNDA Put And Call Options For August 17th

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

VNDA Makes Notable Cross Below Critical Moving Average

VNDA Makes Notable Cross Below Critical Moving Average

In trading on Friday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $15.29, changing hands as low as $15.15 per share. Vanda Pharmaceuticals Inc shares are currently trading down about 1.9% on the day.

First Week of February 2018 Options Trading For Vanda Pharmaceuticals (VNDA)

First Week of February 2018 Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Interesting VNDA Put And Call Options For January 2018

Interesting VNDA Put And Call Options For January 2018

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

Relative Strength Alert For Vanda Pharmaceuticals

Relative Strength Alert For Vanda Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: C+ (Hold)